Company intelligence / Profile preview
Ryvu Therapeutics
Kraków, Małopolska, Polandryvu.com ↗
- Ownership
- Private
- Employees
- ~328
- Development stage
- Phase 2
01
Overview
Ryvu’s lead candidate RVU120, a selective CDK8/CDK19 inhibitor, has reached Phase II clinical trials in hematological malignancies and solid tumors. SEL24/MEN1703/dapolsertib, a dual PIM/FLT3 inhibitor licensed to Menarini Group, has entered Phase II studies for AML and DLBCL. Early pipeline assets target synthetic lethality and immuno-oncology pathways. The company collaborates with major pharma partners such as BioNTech and Exelixis to advance its proprietary technologies into the clinic.[1][2] Updated clinical data from ongoing studies are anticipated throughout late 2025.[5]
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculesAntibody-drug conjugates (ADCs) – novel payloadsImmuno-oncology agents
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
BioNTech SEExelixis Inc.Menarini GroupMerck KGaAGalapagosLeukemia & Lymphoma Society
Beyond the preview
Go deeper on Ryvu Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ryvu Therapeutics.